Investigator

Marie‐Louise F van Velthuysen

Researcher · Erasmus University Rotterdam, Pathology

MFVMarie‐Louise F va…
Papers(1)
Clinicopathological a…
Collaborators(8)
Merijn CF MuldersQuido G de Lussanet d…Wouter W de HerderAnna Vera D VerschuurChristoph GeisenbergerEva Maria RoesJohannes HoflandLodewijk AA Brosens
Institutions(4)
Erasmus McUniversity Medical Ce…LMU KlinikumErasmus MC

Papers

Clinicopathological and epigenetic differences between primary neuroendocrine tumors and neuroendocrine metastases in the ovary

AbstractCurrently, the available literature provides insufficient support to differentiate between primary ovarian neuroendocrine tumors (PON) and neuroendocrine ovarian metastases (NOM) in patients. For this reason, patients with a well‐differentiated ovarian neuroendocrine tumor (NET) were identified through electronic patient records and a nationwide search between 1991 and 2023. Clinical characteristics were collected from electronic patient files. This resulted in the inclusion of 71 patients with NOM and 17 patients with PON. Histologic material was stained for Ki67, SSTR2a, CDX2, PAX8, TTF1, SATB2, ISLET1, OTP, PDX1, and ARX. DNA methylation analysis was performed on a subset of cases. All PON were unilateral and nine were found within a teratoma (PON‐T+). A total of 78% of NOM were bilateral, and none were associated with a teratoma. PON without teratomous components (PON‐T−) displayed a similar insular growth pattern and immunohistochemistry as NOM (p > 0.05). When compared with PON‐T+, PON‐T− more frequently displayed ISLET1 positivity and were larger, and patients were older at diagnosis (p < 0.05). Unsupervised analysis of DNA methylation profiles from tumors of ovarian (n = 16), pancreatic (n = 22), ileal (n = 10), and rectal (n = 7) origin revealed that four of five PON‐T− clustered together with NOM and ileal NET, whereas four of five PON‐T+ grouped with rectum NET. In conclusion, unilateral ovarian NET within a teratoma should be treated as a PON. Ovarian NET localizations without teratomous components have a molecular profile analogous to midgut NET metastases. For these patients, a thorough review of imaging should be performed to identify a possible undetected midgut NET and a corresponding follow‐up strategy may be recommended.

155Works
1Papers
8Collaborators
Neuroendocrine TumorsOvarian NeoplasmsBiomarkers, TumorDiagnosis, DifferentialIntestinal NeoplasmsStomach NeoplasmsCarcinoma, NeuroendocrinePancreatic Neoplasms

Positions

2026–

Researcher

Erasmus University Rotterdam · Pathology

2016–

Attending Pathologist

Erasmus Universiteit Rotterdam · Pathology

2024–

Researcher

Erasmus University Rotterdam · Pathology

2025–

Researcher

Erasmus University Rotterdam · Pathology

2024–

Researcher

Erasmus University Rotterdam · Pathology

2024–

Researcher

Erasmus University Rotterdam · Pathology

2024–

Researcher

Erasmus University Rotterdam · Pathology

2023–

Researcher

Erasmus University Rotterdam · Pathology

2023–

Researcher

Erasmus University Rotterdam · Pathology

2022–

Researcher

Erasmus University Rotterdam · Pathology

2022–

Researcher

Erasmus University Rotterdam · Pathology

2021–

Researcher

Erasmus University Rotterdam · Pathology

2015–

Researcher

Erasmus University Rotterdam · Pathology

1995–

Associate professor

Erasmus University Rotterdam · Pathology

Education

1994

PhD

Leiden University · Pathology

1987

MD

Université de Lausanne Faculté de biologie et médecine

1987

MD

Universiteit Maastricht · Medicine

Country

NL

Keywords
PathologyCytologyAppendixSalivary gland tumorsNeuro Endocrine Neoplasms